SR 202 – 5 mg

Brand:
Cayman
CAS:
76541-72-5
Storage:
-20
UN-No:
Non-Hazardous - /

SR 202 is an antagonist of peroxisome proliferator-activated receptor γ (PPARγ) transcriptional activity induced by troglitazone (Item No. 71750; IC50 = 140 µM) but not of basal PPARγ activity.{10768} It is selective for PPARγ, not affecting basal or agonist-induced transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). It inhibits PPARγ-dependent differentiation of preadipocyte 3T3-L1 cells in a dose-dependent manner. SR 202 (400 mg/kg) decreases the amount of weight gained and white adipose tissue mass accumulated by mice fed a standard or high-fat diet for ten weeks and is associated with lower PPARγ mRNA levels. It protects against high-fat diet-induced insulin resistance in wild-type mice and improves insulin sensitivity in ob/ob mice.  

 

Out of stock

SKU: 21846 - Category:

Description

An antagonist of troglitazone-induced PPARγ transcriptional activity (IC50 = 140 µM); selective for PPARγ, not affecting basal or agonist-induced transcriptional activity of PPARα, PPARβ, or FXR; inhibits PPARγ-dependent differentiation of adipocytes; decreases weight gained and white adipose tissue mass accumulated when administered to mice at a dose of 400 mg/kg for ten weeks; protects against high-fat diet-induced insulin resistance in wild-type mice; improves insulin sensitivity in ob/ob mice


Formal name: phosphoric acid, (4-chlorophenyl)(dimethoxyphosphinyl)methyl dimethyl ester

Synonyms: 

Molecular weight: 358.7

CAS: 76541-72-5

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors|PPARs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity